Pneumonectomy after chemotherapy:: Morbidity, mortality, and long-term outcome

被引:33
作者
Alifano, Marco
Boudaya, Mohamed S.
Salvi, Maurizio
Collet, Jean-Yves
Dinu, Carmen
Camilleri-Broet, Sophie
Regnard, Jean-Francois
机构
[1] Univ Paris Sud, Dept Thorac Surg, AP HP, INSERM,JE2492,Hotel Dieu Hosp, F-75181 Paris, France
[2] Univ Paris Sud, Dept Pathol, AP HP, INSERM,JE2492,Hotel Dieu Hosp, F-75181 Paris, France
[3] Fac Med Paris Descartes, Paris, France
关键词
D O I
10.1016/j.athoracsur.2008.01.103
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Results of pneumonectomy after chemotherapy are controversial, and the procedure is often considered as potentially dangerous. Methods. Records of patients who underwent pneumonectomy after chemotherapy for non-small cell lung cancer in a single institution in a 6-year period were reviewed retrospectively. Results. One hundred eighteen patients had pneumonectomy after chemotherapy. Indications for preoperative chemotherapy were N2 disease, 74; potentially resectable T4 disease, 17; doubtful resectability, 18; stage IV disease (nodule on another ipsilateral lobe), 4; and participation in a randomized trial on induction chemotherapy in initial stages, 5. Chemotherapy protocols were platinum-based. Imaging reevaluation showed complete, partial, minor response, and disease stability in 0, 24, 39, and 55 patients, respectively. Operative mortality was 5.9% (7 of 118), consisting of 4 of 54 after pneumonectomy, and 3 of 64 after left pneumonectomy. Bronchopleural fistula caused one death. No factor among those evaluated (sex, age, comorbidities, forced expiratory volume in 1 second, symptoms, side and location of tumor; indication for operation, number of cycles, and response to chemotherapy; extent of resection, TNM status, pathologic stage) predicted postoperative death. Median and overall 5-year survival was 22 months and 23.7%, respectively. At univariate analysis, pathologic stage, T status, and the occurrence of postoperative complications influenced 5-year survival. At multivariate analysis, T status (p = 0.0054), the occurrence of postoperative complications (p = 0.0015), and clinical response to induction chemotherapy (p = 0.028) were identified as independent predictors of 5-year survival. Conclusions. Pneumonectomy after chemotherapy has acceptable mortality. Long-term results are encouraging.
引用
收藏
页码:1866 / 1873
页数:8
相关论文
共 19 条
[1]   A new method for detection of post-pneumonectomy broncho-pleural fistulas [J].
Alifano, M ;
Sepulveda, S ;
Mulot, A ;
Schussler, O ;
Regnard, JF .
ANNALS OF THORACIC SURGERY, 2003, 75 (05) :1662-1664
[2]   Adjuvant and neoadjuvant chemotherapy in NSCLC: a paradigm shift [J].
Betticher, DC .
LUNG CANCER, 2005, 50 :S9-S16
[3]   Impact of induction treatment on postoperative complications in the treatment of non-small cell lung cancer [J].
Brouchet, Laurent ;
Bauvin, Eric ;
Marcheix, Bertrand ;
Bigay-Game, Laurence ;
Renaud, Claire ;
Berjaud, Jean ;
Falcoze, Pierre Emmanuel ;
Venissac, Nicolas ;
Raz, Dan ;
Jablons, David ;
Mazieres, Julien ;
Dahan, Marcel .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (07) :626-631
[4]   Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer [J].
Depierre, A ;
Milleron, B ;
Moro-Sibilot, D ;
Chevret, S ;
Quoix, E ;
Lebeau, B ;
Braun, D ;
Breton, JL ;
Lemarié, E ;
Gouva, S ;
Paillot, N ;
Bréchot, JM ;
Janicot, H ;
Lebas, FX ;
Terrioux, P ;
Clavier, J ;
Foucher, P ;
Monchâtre, M ;
Coëtmeur, D ;
Level, MC ;
Leclerc, P ;
Blanchon, F ;
Rodier, JM ;
Thiberville, L ;
Villeneuve, A ;
Westeel, V ;
Chastang, C .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :247-253
[5]   One hundred consecutive pneumonectornies after induction therapy for non-small cell lung cancer: An uncertain balance between risks and benefits [J].
Doddoli, C ;
Barlesi, F ;
Trousse, D ;
Robitail, S ;
Yena, S ;
Astoul, P ;
Giudicelli, R ;
Fuentes, P ;
Thomas, P .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2005, 130 (02) :416-425
[6]   Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]):: a randomised controlled trial [J].
Douillard, Jean-Yves ;
Rosell, Rafael ;
De Lena, Mario ;
Carpagnano, Francesco ;
Ramlau, Rodryg ;
Gonzales-Larriba, Jose Luis ;
Grodzki, Tornasz ;
Pereira, Jose Rodrigues ;
Le Groumellec, Alain ;
Lorusso, Vito ;
Clary, Claude ;
Torres, Antonio J. ;
Dahabreh, Jabrail ;
Souquet, Pierre-Jean ;
Astudillo, Julio ;
Fournel, Pierre ;
Artal-Cortes, Angel ;
Jassem, Jacek ;
Koubkova, Leona ;
His, Patricia ;
Riggi, Marcella ;
Hurteloup, Patrick .
LANCET ONCOLOGY, 2006, 7 (09) :719-727
[7]   POSTOPERATIVE COMPLICATIONS AFTER COMBINED NEOADJUVANT TREATMENT OF LUNG-CANCER [J].
FOWLER, WC ;
LANGER, CJ ;
CURRAN, WJ ;
KELLER, SM .
ANNALS OF THORACIC SURGERY, 1993, 55 (04) :986-989
[8]   Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer [J].
Le Chevalier, T ;
Arriagada, R ;
Le Péchoux, C ;
Grunenwald, D ;
Dunant, A ;
Pignon, JP ;
Tarayre, M ;
Abratt, R ;
Arriagada, R ;
Bergman, B ;
Gralla, R ;
Grunenwald, D ;
Le Chevalier, T ;
Orlowski, T ;
Papadakis, E ;
Pinel, MIS ;
Araujo, C ;
Della Torre, H ;
de Solchaga, MM ;
Abdi, E ;
Blum, R ;
Ball, D ;
Basser, R ;
De Boer, R ;
Bishop, J ;
Brigham, B ;
Davis, S ;
Fox, D ;
Richardson, G ;
Wyld, D ;
Pirker, R ;
Humblet, Y ;
Delaunois, L ;
Van Meerbeeck, JP ;
Germonpre, P ;
Vansteenkiste, J ;
Nackaerts, K ;
Pinel, MIS ;
Vauthier, G ;
Younes, RN ;
Arriagada, R ;
Baeza, R ;
Carvajal, P ;
Kleinman, S ;
Orlandi, L ;
Castro, C ;
Godoy, J ;
Kosatova, K ;
Gaafar, R ;
Azarian, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (04) :351-360
[9]   Does chemotherapy increase the risk of respiratory complications after pneumonectomy? [J].
Leo, Francesco ;
Solli, PierGiorgio ;
Veronesi, Giulia ;
Radice, Davide ;
Floridi, Antonio ;
Gasparri, Roberto ;
Petrella, Francesco ;
Borri, Alessandro ;
Galetta, Domenico ;
Spaggiari, Lorenzo .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2006, 132 (03) :519-523
[10]   Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience [J].
Lorent, N ;
De Leyn, P ;
Lievens, Y ;
Verbeken, E ;
Nackaerts, K ;
Dooms, C ;
Van Raemdonck, D ;
Anrys, B ;
Vansteenkiste, J .
ANNALS OF ONCOLOGY, 2004, 15 (11) :1645-1653